The pharmacological basis of anti-IgE therapy

Nature Biotechnology

Volumn 18, Issue 2, 2000, Pages 157-162

  Chang, Tse Wen ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Allergy; Anti IgE; Asthma; Fc RI; Humanized antibodies; Immune complexes; Immunoglobulin E

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC RHINITIS; ALLERGY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ASTHMA; B LYMPHOCYTE ACTIVATION; COMPLEX FORMATION; DESENSITIZATION; DRUG EFFECT; HUMAN; MEDIATOR RELEASE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW;

ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; RHINITIS;

ANIMALIA;

EID: 0000898623     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/72601     Document Type: Review

References (61)

1. Janeway, C.A., Travers, P. & Walport, M. Immunobiology: the immune system in health and disease, Edn. 4 (Elsevier Science Ltd., London; 1999).
2. Carter, S.E. & Patts-Mills, T.A. Searching for the cause of the increase in asthma. Curr. Opin. Pediatr. 10, 594-599 (1998).
3. Lundback, B. Epidemiology of rhinitis and asthma. Clin. Exp. Allergy 28 (suppl. 2), 3-10 (1998).
4. Juniper, E.F. Quality of life in adults and children with asthma and rhinitis. Allergy 52, 971-977 (1997).
5. Smith, D.H. et al. A national estimate of the economic costs of asthma. Am. J. Respir. Crit. Care Med. 156, 787-793 (1997).
6. O'Hehir, R.E., Gamen, R.D., Greenstein, J.L. & Lamb, J.R. The specificity and regulation of T-cell responsiveness to allergens. Annu. Rev. Immunol. 9, 67-95 (1991).
7. Durham, S.R. et al. Long-term clinical efficacy of grass pollen immunotherapy. N. Engl. J. Med. 341, 468-475 (1999).
8. Davis, F.M. et al. Can anti-IgE be used to treat allergy? Springer Semin. Immunopathol. 15, 51-73 (1993).
9. Heusser, C. & Jardieu, P. Therapeutic potential of anti-IgE antibodies. Curr. Opin. Immunol. 9, 805-813 (1997).
10. Corne, J. et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J. Clin. Invest. 99, 879-887 (1997).
11. Racine-Poon, A. et al. Clinical efficacy of CGP 51901, an anti-IgE chimeric monoclonal antibody, in patients with allergic rhinitis: is it related to the extent of IgE suppression and pharmacokinetics? Clin. Pharmcol. Ther. 62, 675-690 (1997).
12. Kolbinger, F., Saldanha, J., Hardman, N. & Bendig, M.M. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Eng. 6, 971-980 (1993).
13. Presta, L.G. et al. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623-2632 (1993).
14. Fahy, J.V. et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic patients. Am. J. Respir. Crit. Care Med. 155, 1824-1834 (1997).
15. Boulet, L.P. et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am. J. Respir. Crit. Care Med. 155, 1835-1840 (1997).
16. Milgrom, E. et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N. Engl. J. Med. 341, 1966-1973 (1999).
17. th Nordic Congress of Allergology, Oslo, Norway, May 14, 1999.
18. Demoly, P & Bousquet, J. Anti-IgE therapy for asthma. Am. J. Respir. Crit. Care Med. 155, 1825-1827 (1997).
19. Barnes, P.J. Anti-IgE antibody therapy for asthma. N. Engl. J. Med. 341, 2006-2008 (1999).
20. Chang, T.W. Treating hypersensitivities with anti-IgE monoclonal antibodies that bind to IgE-expressing B cells but not to basophils. US Patent 5,543, 144 (1996).
21. Chang, T.W. et al. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Bio/Technology 8, 122-126 (1990).
22. Bialy, H. Can antibodies to IgE act as anti-allergies? Bio/Technology 8, 96 (1990).
23. Hook, W.A., Zinsser, F.U.. Berenstein, E.H. & Siraganian, R.P. Monoclonal antibodies defining epitopes on human IgE. Mol. Immunol. 28, 631-639 (1991).
24. MacGlashan, D.W. Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. J. Allergy Clin. Immunol. 91, 605-615 (1993).
25. Helm, B. et al. Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ε-chain fragment of 76 amino acids. Proc. Natl. Acad. Sci. USA 86, 9465-9469 (1989).
26. Nissim, A., Jouvin, M.H. & Eshhar, Z. Mapping of the high affinity Fc epsilon receptor binding site to the third constant domain of IgE. EMBO J. 10, 101-107 (1991).
27. Presta, L. et al. The binding site on human immunoglobulin E for its high affinity receptor. J. Biol. Chem. 269, 26368-26373 (1994).
28. Henry, A.J. et al. Participation of the N-terminal region of Cε3 in the binding of human IgE to its high-affinity receptor FcεRI. Biochemistry 36, 15568-15578 (1997).
29. Wright, J.D. & Lim, C. Prediction of an anti-IgE binding site on IgE. Protein Eng. 11, 421-427 (1998).
30. Zheng, Y., Shopes, B., Holowka, D. & Baird, B. Conformations of IgE bound to its receptor FcεRI and in solution. Biochemistry 30, 9125-9132 (1991).
31. Keown, M.B., Ghirlando, R., Mackay, G.A., Sutton, B.J. & Gould, H.J. Basis of the 1:1 stoichiometry of the high affinity receptor FcεRI-IgE complex. Eur. Biophys. J. 25, 471-476 (1997).
32. Sechi, S., Roller, P.P., Willette-Brown, J. & Kinet, J.P. A conformational rearrangement upon binding of IgE to its high affinity receptor. J. Biol. Chem. 271, 19256-19263 (1996).
33. Keown, M.B., Henry, A.J., Ghirlando, R., Sutton, B.J. & Gould, H.J. Thermodynamics of the interaction of human immunoglobulin E with its high-affinity receptor FcεRI. Biochemistry 23, 8863-8869 (1998).
34. Dierks, S.E. et al. The oligomeric nature of the murine FcεRII/CD23. Implications for function. J. Immunol. 150, 2372-2382 (1993).
35. Sutton, B.J. & Gould, H.J. The human IgE network. Nature 366, 421-428 (1993).
36. Stämpfli, M.R., Miescher, S., Aebischer, I., Zurcher, A.W. & Stadler, B.M. Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition. Eur. J. Immunol. 24, 2161-2167 (1994).
37. Peng, C. et al. A new isoform of human membrane-bound IgE. J. Immunol. 148, 129-136 (1992).
38. Reth, M. B-cell antigen receptors. Curr. Opin. Immunol. 6, 3-8 (1994).
39. Miller, L., Blank, U., Metzger, H. & Kinet, J.P. Expression of high-affinity binding of human immunoglobulin E by transfected cells. Science 244, 334-337 (1989).
40. Zetterstrom, O. & Johansson, S.G. IgE concentrations measured by PRIST in serum of healthy adults and in patients with respiratory allergy. A diagnostic approach. Allergy 36, 537-547 (1981).
41. Warner, G.L. & Scott, D.W. A polyclonal model for B cell tolerance. Fc-dependent and Fc-independent induction of nonresponsiveness by pretreatment of normal splenic B cells with anti-Ig. J. Immunol. 146, 2185-2191 (1991).
42. Eray, M. et al. Cross-linking of surface IgG induces apoptosis in a bcl-2 expressing human follicular lymphoma line of mature B cell phenotype. Int. Immunol. 6, 1817-1827 (1994).
43. Heusser, C.H. et al. Demonstration of the therapeutic potential of non-anaphylactogenic anti-IgE antibodies in murine models of skin reaction, lung function and inflammation. Int. Arch. Allergy Immunol. 113, 231-235 (1997).
44. Haba, S. & Nisonoff, A. Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. J. Immunol. 152, 51-57 (1994).
45. Manoney, D.G. et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15, 3266-3274 (1997).
46. Peeters, S.H. & Carter, B.G. Regulation of the IgE antibody response in mice. II. radioresistance of established IgE antibody production. Immunology 43, 25-32 (1981).
47. Vitetta, E.S. et al. Memory B and T cells. Ann. Rev. Immunol. 9, 193-217 (1991).
48. Haba, S. & Nisonoff, A. Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. J. Immunol. 152, 51-57 (1994).
49. Ogawa, M. et al. Biologic properties of E myeloma proteins. Am. J. Med. 51, 193-199 (1971).
50. Liu, J., Lester, P., Builder, S. & Shire, S.J. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34, 10474-10482 (1995).
51. Peng, Z.K., Naclerio, R.M., Norman, P.S. & Adkinson, N.F. Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy. J. Allergy Clin. Immunol. 89, 519-529 (1992).
52. Chen, H.D. Chen, C.L. & Huang, S.W. Characterization of latex allergens and correlation of serum IgE/IgG antibody ratio with clinical symptoms. Allergy Asthma Proc. 17, 143-148 (1996).
53. Celis, E. & Chang, T.W. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science 224, 297-299 (1984).
54. Liu, C., Gosselin, E.J. & Guyre, P.M. FcεRII on human B cells can mediate enhanced antigen presentation. Cell Immunol. 167, 188-194 (1996).
55. Muddle, G.C., Bheekha, R. & Bruijnzeel-Koomen, C.A. Consequences of IgE/CD23-mediated antigen presentation in allergy. Immunol. Today 16, 380-383 (1995).
56. Maurer, D. et al. The high affinity IgE receptor (FcεRI) mediates IgE-dependent allergen presentation. J. Immunol. 154, 6285-6290 (1995).
57. Malveaux, F.J., Conroy, M.C., Adkinson, N.F. & Lichtenstein, L.M. IgE receptors on human basophils. Relationship to serum IgE concentration. J. Clin. Invest. 62, 176-181 (1978).
58. MacGlashan, D.W. et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 158, 1438-1445 (1997).
59. MacGlashan, D.W et al. In vitro regulation of FcεRIα expression on human basophils by IgE antibody. Blood 91, 1633-1643 (1998).
60. Lantz, C.S. et al. IgE regulates mouse basophil FcεRI expression in vivo. J. Immunol. 158, 2517-2521 (1997).
61. LoBuglio, A.F. et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA 86, 4220-4224 (1989).